Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells

R Thaler1, S Spitzer, H Karlic

  • 1Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria.

Biochemical Pharmacology
|October 30, 2012
PubMed

Insights

Aminobisphosphonates like ibandronate induce cancer cell death by inhibiting small GTPase activity. This epigenetic mechanism involves DNA demethylation and FAS gene upregulation, leading to apoptosis in neoplastic cells.

Area of Science:

  • Biochemistry
  • Epigenetics
  • Cancer Biology

Background:

  • Aminobisphosphonates, such as ibandronate, exhibit anticancer effects through poorly understood mechanisms.
  • These drugs inhibit the posttranslational isoprenylation of small GTPases, crucial for cell signaling.
  • In cancer cells, activated RAS-GTPase downregulates the pro-apoptotic FAS gene via DNA methylation mediated by DNMT1.

Purpose of the Study:

  • To investigate the anticancer mechanism of ibandronate in neoplastic and non-neoplastic cells.
  • To determine the effect of ibandronate on cell proliferation, apoptosis, and gene expression.
  • To elucidate the role of epigenetic modifications, specifically DNA methylation and demethylation, in ibandronate's action.

Main Methods:

  • Treatment of human osteosarcoma (U-2) and mouse breast cancer (CCL-51) cells, alongside non-neoplastic osteoblastic (MC3T3-E1) cells, with ibandronate.
  • Assessment of cell proliferation rates across all cell lines.
  • Analysis of caspase activation, FAS expression, DNMT1 levels, and DNA methylation status following ibandronate treatment.
  • Investigation of the rescue effect of geranylgeranyl-pyrophosphate and farnesylpyrophosphate on DNMT1 activity.

Main Results:

  • Ibandronate attenuated proliferation in all tested cell lines.
  • Neoplastic cells exhibited increased caspase activity, indicating apoptosis.
  • FAS expression was upregulated in cancer cells due to DNA demethylation, linked to DNMT1 downregulation.
  • DNMT1 downregulation was reversible by re-isoprenylation, while non-neoplastic cells showed no changes in FAS or DNMT1 expression.

Conclusions:

  • Bisphosphonates induce apoptosis in neoplastic cells by modulating small GTPase activity, leading to DNA-CpG demethylation and FAS expression stimulation.
  • This epigenetic mechanism explains the anti-neoplastic activity of farnesyl-transferase inhibition.
  • The findings provide insight into the clinical efficacy of drugs targeting this pathway.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...